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A 2 kilobase pair cDNA coding for the entire C-terminal catalytic domain of rat poly(ADP-riiose)polymerase has been expressed in E. coli. The 
overproduced 55 kDa polypeptide is active in synthesizing poly(ADP-ribose) and the 4 kDa N-terminal region of this domain is recognized by 
the monoclonal antibody C I,2 directed against he calf enzyme. Also, the minor a-chymotrypsin cleavage site found in the human catalytic domain 
is not present in the rat enzyme as revealed by the absence of the 40 kDa specific degradation product in the E. coli cells expressing the rat domain. 
The expression of this partial rat cDNA should thus permit the rapid purification and subsequent crystallization of the catalytic domain of the 
enzyme. 
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1. INTRODUCTION 
Poly(ADP-ribose)polymerase (PARP) is a nuclear 
enzyme that catalyzes the covalent attachment and 
elongation of poly(ADP-ribose) from NAD+ on 
nuclear proteins such as histones, topoisomerase I and 
PARP (automodification) (for review, see [l]). Poly- 
(ADP-ribose) is implicated in nuclear events including 
the relaxation of chromatin, DNA repair and gene ex- 
pression. PARP can be divided into three functional 
domains when treated with papain and a-chymotrypsin 
[2-41. The N-terminal 42 kDa domain contains 2 zinc- 
finger motifs that bind specifically to DNA single 
strand breaks [5,6]. The internal 16 kDa is the 
automodification domain while the C-terminal 55 kDa 
domain binds NAD+ and is the catalytic region. 
We have recently cloned a partial rat cDNA coding 
for the entire catalytic domain of the enzyme [7]. The 
predicted amino acid sequence is greater than 95% 
homologous to the same domain of the human [3,8-lo] 
and mouse [l l] proteins. Most importantly this domain 
was shown to be the target of autoantibodies against 
the PARP in several human rheumatic patients [ 121. As 
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a first step toward the purification and crystallization 
of the catalytic domain, we have expressed in E. coli the 
rat cDNA coding for this region of the PARP. 
2. MATERIALS AND METHODS 
2.1. Expression in E. coli 
We have used a rat cDNA which is one bp (cytosine) longer at the 
5’ end than the one described previously [7]. It was inserted in the 
EcoRI site of pTG161 [13] to give the recombinant plasmid, 
pTGrat55. We have also cloned a Hind111 fragment of the human 
PARP cDNA [lo] in the plasmid pTG920 [13]. This 2.66 kbp frag- 
ment (pTGhum87) starts at the nucleotide position +698 [3] and 
codes for the catalytic domain, the automodification domain and 
part of the DNA binding domain. The plasmid pTG161 SHl.4 codes 
for the C-terminal 51 kDa part of the human catalytic domain, 
starting from the amino acid 572 corresponding to the PstI site [3]. 
E. coli TGE 900 was transformed with the recombinant plasmids, 
grown at 28°C and shifted to 37°C to induce the transcription of the 
foreign PARP sequences [13]. Preparation, SDS-PAGE and elec- 
trophoretic transfer of the crude extracts on the solid support were 
as described [14]. 
2.2. Detection methods 
The PARP-specific polypeptides were revealed on the nitrocel- 
lulose sheet by 2 methods as described [14]. First, an activity blot 
using [32P]NAD+ was done in the presence of calf thymus DNA. The 
immunogenic fragments were then revealed using monoclonal and 
polyclonal antibodies against the PARP [4] and second antibodies 
conjugated to alkaline phosphatase [6]. 
3. RESULTS AND DISCUSSION 
We have compared the expression in E. coli of the 
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Fig. 1. Expression f the cloned PARP fragments in E. coli. Gel elec- 
trophoresis of the crude extracts from uninduced (28°C) and induced 
(37°C) cells transformed with (1) pTGhum87, (2) pTGrat55, (3) 
pTG161 SH1.4. (M) molecular weight markers in kDa. Black dots in- 
dicate the position of the overexpressed proteins. 
rat (pTGrat55) and human (PTG161 SH1.4, 
pTGhum87) cDNA fragments, all encoding the 
catalytic domain of the PARP. Analysis of the crude 
extracts showed that these fragments are overexpressed 
in induced cells and code for polypeptides of the ex- 
pected molecular weights (Fig. 1). These overproduced 
proteins (87, 54 and 5 1 kDa) are recognized on Western 
blot by a rabbit polyclonaf antiserum (Fig. 2A). This 
antibody also revealed in human HeLa and Rat-l 
cellular extracts the 113 kDa PARP as well as many 
other smaller polypeptides that come from endogenous 
degradation of the enzyme (Fig. 2A, lanes 1,4) [15]. 
The expression in E. coli of the pTGhum87 plasmid 
(Fig. 2A, lane 2) as well as other human cDNA frag- 
h PARP (650) E A V K K L’T V N P G (660) 
bPARP - EAVKKLTVNPG - 
IllPARP - EAVKKLTVKPG - 
rPARP - EAVKKATVKPG - 
Fig. 3. Analysis of amino acid sequence homology of the minor (Y- 
chymotrypsin cleavage site of the PARP. Arrow indicates the 
cleavage site [6,23]. (h) human [3]; (b) bovine [18]; (m) mouse (111; 
(r) rat [7]. Bold letters represents an amino acid variation to the 
human sequence. 
ments [lo, 161 also produced many lower molecular 
weight PARP-related polypeptides in addition to the 
overexpressed proteins. When a small part of the 
human cDNA (pTG161 SH1.4) coding only for the C- 
terminal 51 kDa region of the catalytic domain is ex- 
pressed in E. cob, we still observe a major 40 kDa con- 
taminant (Fig. 2A, lane 3). Neither of these fragments 
nor any other contaminants were ever detected in cells 
expressing the rat 55 kDa domain (Fig. 2, lane 5). Since 
the human [lo] and rat [7] sequences are homologous 
around the catalytic domain putative internal start site 
(not shown) described before [lo], we feel that this 40 
kDa fragment more likely derives from the cleavage of 
the human domain by an endogenous a-chymotrypsin- 
like protease of E. co/i. a-Chymotrypsin was previous- 
ly shown to cut in the human [17] and bovine [2,4,18] 
55 kDa catalytic domain to generate 40 and 15 kDa 
fragments. We thus compared the predicted amino acid 
sequence of the PARP from different organisms at this 
cleavage site (Fig. 3). The substitution of the leucine 
655 for an alanine in the rat sequence could explain the 
resistance of this region to the hypothesized a-chymo- 
trypsin-like protease of E. coli. The activity blot in 
Fig. 2B reveals that upon incubation with [32P]NAD+, 
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Fig. 2. Analysis of the overexpressed PARP-specific proteins. (A) 
Immunodetection with a purified polyclonal antibody directed 
against calf thymus PARP. (B) Activity blot. Lane 1, HeLa cell ex- 
tract; lane 2, pTGhum87; lane 3, pTG1161 SH1.4; lane 4, Rat-l cell 
extract; lane 5, pTGrat55. (M) as Fig. 1. 
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Fig. 4. lmmunoreactivity of monoclonal antibody C 1,2. Crude 
E. co/i extracts from induced cells transformed with (a) pTGhum87; 
(b) pTGrat55; (c) pTG161 SH1.4. (M) as in Fig. I. 
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the overexpressed rat 55 kDa fragment is active in syn- 
thesizing poly(ADP-ribose). Taken together these data 
show that the rat cDNA is the most suitable choice for 
the overexpression, purification and crystallization at- 
tempts of the PARP catalytic domain. 
Finally, the difference in size between the rat 55 kDa 
fragment (which is recognized by the monoclonal an- 
tibody C 1,2) and the human 51 kDa fragment (which 
is not (Fig. 4)), represents the epitope of this antibody. 
This region is part of the 15 kDa a-chymotrypsic frag- 
ment recognized by human autoantibodies [121. Unlike 
these antibodies C I,2 does not inhibit the activity of 
the PARP [4] suggesting that their epitopes are dif- 
ferent. However, both map outside the 40 kDa frag- 
ment which is still active (Fig. 2B, lane 3) and contains 
the highly conserved putative nucleotide binding site 
[71 f 
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